Valenzuela Reuben M, Rai Ruju, Kirk Brian H, Sanders Jessica N, Sundar Subhashree, Hamann Steffen, Warner Judith E A, Digre Kathleen B, Crum Alison V, Jones Kirtly P, Katz Bradley J
Department of Ophthalmology and Visual Sciences; John A. Moran Eye Center, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
Department of Neurology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
Neuroophthalmology. 2017 Apr 19;41(4):192-197. doi: 10.1080/01658107.2017.1304425. eCollection 2017 Aug.
Because of a previous association of pseudotumor cerebri (PTC) with levonorgestrel, we wished to evaluate the use of levonorgestrel-eluting intrauterine devices ("levonorgestrel intrauterine systems", LNG-IUS) in our University of Utah and Rigshospitalet PTC patients. In our retrospective series, PTC prevalence was approximately 0.18% and 0.15% in the LNG-IUS population versus 0.02% and 0.04% in the non-LNG-IUS population (Utah and Rigshospitalet, respectively), with no significant differences in PTC signs and symptoms among the two groups. Our investigation suggests that women with an LNG-IUS may have increased risk of developing PTC but does not suggest an LNG-IUS can cause PTC.
由于此前曾发现假性脑瘤（PTC）与左炔诺孕酮有关联，我们希望评估左炔诺孕酮宫内节育器（“左炔诺孕酮宫内系统”，LNG-IUS）在我们犹他大学和丹麦哥本哈根大学医院的PTC患者中的使用情况。在我们的回顾性系列研究中，LNG-IUS人群中PTC的患病率分别约为0.18%和0.15%，而非LNG-IUS人群中PTC的患病率分别为0.02%和0.04%（分别来自犹他大学和丹麦哥本哈根大学医院），两组之间PTC的体征和症状无显著差异。我们的调查表明，使用LNG-IUS的女性患PTC的风险可能会增加，但并未表明LNG-IUS会导致PTC。
